Does Cigna Cover Provigil (Modafinil)?

What FDA Indications Does Provigil Carry, and Why Does That Matter for Cigna?

Cigna's medical and pharmacy policies are anchored to FDA-labeled indications. Provigil holds three: narcolepsy, OSA with residual excessive sleepiness despite adequate CPAP therapy, and SWSD [1]. Any claim submitted under a diagnosis code outside these three categories is classified as off-label, which triggers automatic denial on nearly every Cigna commercial plan. The 1998 US Modafinil in Narcolepsy Multicenter Study Group trial (N=271, published in Annals of Neurology) established 200 mg and 400 mg modafinil as significantly more effective than placebo for reducing daytime sleepiness scores, producing a mean Epworth Sleepiness Scale improvement of 2.2 points over placebo at eight weeks (P<0.001) [2]. That trial data formed the backbone of FDA labeling and is the same evidence Cigna's pharmacy policy document cites when defining "medically necessary" use.

Cigna's pharmacy benefit management division contracts with Express Scripts (now Evernorth). Because Evernorth maintains its own formulary, a Cigna member's actual tier placement depends on which specific Cigna plan they hold, commercial individual-market, employer-sponsored, or Cigna Medicare Advantage. The brand-name Provigil (manufactured by Jazz Pharmaceuticals after the original Cephalon patent) sits on Tier 3 or Tier 4 on most commercial formularies, while generic modafinil occupies Tier 2 as a preferred generic [3].

The practical consequence: even with Cigna's standard cost-sharing for a Tier 3 drug, a 30-day supply of brand Provigil can cost a member $150, $350 in copay after the deductible. Generic modafinil on Tier 2 might run $10, $45 for the same supply. Understanding your plan's specific tier structure before the prescription is written saves money and reduces the likelihood of a surprise denial at the pharmacy counter.

Cigna's coverage policies are publicly accessible through the Cigna coverage policy library [4]. Searching "modafinil" or "wakefulness-promoting agents" returns the current policy number, which your prescriber's office should reference in any prior authorization submission.

What Are Cigna's Prior Authorization Criteria for Provigil?

Prior authorization for brand Provigil on Cigna requires documentation of a confirmed diagnosis, a qualifying sleep study, and in most cases a demonstrated step-therapy trial with generic modafinil. Cigna will not approve brand Provigil without a formal prior authorization submission from the prescribing clinician [5].

The standard documentation package includes:

Confirmed diagnosis. The prescriber must document narcolepsy (ICD-10 G47.419 or G47.411), OSA (G47.33) with active or documented CPAP therapy, or SWSD (G47.26). A letter of medical necessity alone is insufficient without the corresponding ICD-10 code on the PA form.

Objective sleep study. For narcolepsy, Cigna requires a polysomnography (PSG) plus a Multiple Sleep Latency Test (MSLT) showing a mean sleep latency of 8 minutes or less and two or more sleep-onset REM periods. For OSA, documentation must confirm that CPAP therapy is in use and that residual excessive daytime sleepiness (EDS) persists despite adequate adherence (typically 4+ hours per night, 70% of nights over 30 days), consistent with the American Academy of Sleep Medicine guidelines [6]. For SWSD, documentation of a rotating or night-shift work schedule is required alongside a diary or actigraphy report.

Step therapy with generic modafinil. Cigna requires that the member has tried generic modafinil at an adequate dose (200 mg daily, titrating to 400 mg if tolerated) for a minimum trial period, typically 30 days, unless the prescriber documents a specific clinical reason why the brand formulation is medically necessary over the generic. Because modafinil generic and brand Provigil contain identical active ingredients at identical doses, this step is rarely bypassed [7].

Prescriber specialty. Cigna's PA forms for Provigil carry higher approval rates when submitted by a board-certified sleep medicine physician, neurologist, or pulmonologist. Primary care submissions are reviewed but face additional scrutiny.

Once the PA package is submitted via Cigna's provider portal (accessible at cigna.com/providers), the standard review window is 3, 5 business days. An urgent PA, justified when a delay could cause serious harm, must be decided within 72 hours by federal law under the Mental Health Parity and Addiction Equity Act provisions and CMS managed care rules [8].

What Tier Is Provigil on the Cigna Formulary?

Brand-name Provigil is most commonly placed on Tier 3 (non-preferred brand) or Tier 4 (specialty or high-cost brand) across Cigna's commercial plan formularies, while generic modafinil sits on Tier 2 as a preferred generic. Tier placement directly determines your copay structure and whether step therapy applies.

Cigna's formulary changes occur annually on January 1, and mid-year formulary updates can also alter tier status. The Evernorth drug formulary search tool allows members to look up the exact tier for their specific plan by entering their member ID or plan name [9]. A drug listed as "covered with restrictions" in the formulary search means PA is required before the claim will process.

For employer-sponsored Cigna plans, the formulary is set by the employer's benefits selection. Some large self-insured employers negotiate custom formularies with Cigna that place generic modafinil on Tier 1 with a $0 copay, particularly employers with high proportions of shift workers (airlines, hospitals, manufacturing). If your plan is employer-sponsored, your HR benefits team can request the Summary Plan Description (SPD), which lists every formulary tier and associated cost-sharing.

One data point worth knowing: the FDA approved six generic modafinil manufacturers between 2012 and 2016, collapsing the cash price from over $700 per month to under $80 [10]. That price collapse is precisely why Cigna's step therapy protocol defaults to generic first. The clinical outcomes data shows no meaningful difference in efficacy between brand and generic modafinil because they share the same API and bioequivalence standards, a point confirmed in the FDA's Orange Book listing for modafinil [11].

Does Cigna Require Step Therapy Before Approving Provigil?

Yes. Cigna's standard wakefulness-promoting agent policy requires a documented trial of generic modafinil before the plan will approve brand Provigil, unless the member documents an allergy, intolerance, or a plan-specific exception. Step therapy does not typically apply between modafinil and armodafinil (Nuvigil), which is a separate molecule and carries its own PA pathway [12].

The step therapy trial period is generally 30 days at a therapeutic dose. If the member experiences an adverse reaction to generic modafinil, such as headache, nausea, anxiety, or insomnia, and the prescriber documents that reaction in the PA submission, Cigna may waive the brand step-therapy requirement. However, the adverse reaction must be documented in a clinical note dated during the trial period, not retrospectively stated in a letter.

Federal law under the 21st Century Cures Act and many state step therapy reform laws now require insurers to grant step therapy exceptions within 72 hours (24 hours for urgent cases) when a clinician attests that the required step drug is contraindicated, was tried and failed, or would cause a clinically significant adverse outcome [13]. As of 2025, 37 states have enacted step therapy exception laws that apply to state-regulated fully-insured Cigna plans. Self-insured ERISA plans are not bound by state step therapy laws, but many choose to follow them voluntarily.

The HealthRX clinical team uses a four-item checklist when preparing a step-therapy exception request for Provigil on Cigna: (1) a dated clinical note documenting the adverse reaction or therapeutic failure during the generic trial; (2) a letter of medical necessity explicitly citing the Cigna policy number and the applicable federal or state step-therapy exception statute; (3) the objective sleep study report; and (4) a completed Cigna PA form with ICD-10 codes filled by the prescriber, not the front desk.

How Do I Appeal a Cigna Denial of Provigil?

Cigna operates a two-level internal appeal process followed by an external independent review, and winning requires a different document package at each stage. A denial is not the end of the road [14].

Level 1 Internal Appeal. Submit within 180 days of the denial notice. Include the original denial letter, the prescriber's letter of medical necessity (citing specific clinical findings, not boilerplate language), the sleep study report, any peer-reviewed literature supporting the medical necessity of brand over generic (if that was the denial basis), and a completed Cigna appeal form. Cigna must respond within 30 days for post-service appeals and 15 days for pre-service appeals under ERISA plan rules.

The American Academy of Sleep Medicine's International Classification of Sleep Disorders, Third Edition (ICSD-3) defines narcolepsy Type 1 as requiring a mean MSLT latency of 8 minutes or less and cataplexy or cerebrospinal fluid hypocretin-1 levels at or below 110 pg/mL [15]. Quoting the ICSD-3 criteria in your appeal letter and confirming your diagnosis meets them strengthens the clinical argument considerably.

Level 2 Internal Appeal. If Level 1 is denied, you have another internal appeal right. Cigna must assign a different reviewer who was not involved in the Level 1 decision. Response timelines mirror Level 1. This is the stage where a board-certified sleep medicine physician writing directly to Cigna's medical director carries the most weight.

External Independent Review (IRO). After exhausting internal appeals, members may request review by an external IRO at no cost. Under the Affordable Care Act and most state insurance codes, Cigna must comply with the IRO's decision. Published IRO reversal data from state insurance departments shows that claimants who submit specialty-physician support letters and objective diagnostic evidence win external reviews approximately 40% of the time [16].

Expedited Appeal. If a standard appeal timeline would seriously jeopardize health, the member or prescriber may request an expedited appeal. Cigna must decide within 72 hours.

Can I Use a Manufacturer Savings Card With Cigna?

Manufacturer copay cards for brand Provigil cannot be used with federal or state government insurance programs (Medicare, Medicaid, TRICARE), but they are generally usable with commercial Cigna plans for eligible members. Jazz Pharmaceuticals has historically offered a Provigil savings program reducing out-of-pocket cost to $5, $30 per month for commercially insured patients who meet income criteria.

The catch: Cigna and many other commercial insurers have adopted "accumulator adjustment programs" (AAPs) that prevent manufacturer copay assistance from counting toward your annual deductible or out-of-pocket maximum [17]. Under an AAP, the copay card pays the pharmacy, but Cigna does not credit that payment toward your deductible. You effectively pay your full deductible in real medical expenses before cost-sharing kicks in.

Checking whether your specific Cigna plan uses an accumulator adjuster requires a call to Cigna member services (the number on the back of your insurance card) or a direct review of your plan's Summary of Benefits and Coverage (SBC) document, which must list accumulator adjustment program use by law under the No Surprises Act transparency provisions [18].

Does Cigna Cover Provigil for Weight Loss or Off-Label Cognitive Enhancement?

No. Cigna does not cover Provigil or modafinil for weight loss, cognitive enhancement, fatigue without a qualifying sleep diagnosis, depression augmentation, or any other off-label use under its standard commercial policies. Claims submitted with a non-qualifying diagnosis code are automatically denied at the pharmacy claims adjudication level before a human reviewer even sees them.

The off-label interest in modafinil for cognition is driven by a 2015 systematic review in European Neuropsychopharmacology (19 blinded placebo-controlled trials) that found modafinil improved performance on attention, executive function, and learning tasks in non-sleep-deprived individuals, with effect sizes in the small-to-moderate range [19]. That review is a legitimate piece of evidence for off-label use but does not meet Cigna's "medically necessary" threshold, which requires an FDA-approved indication or a compendia listing (Drugdex, Clinical Pharmacology) for the off-label use.

For weight loss specifically, no major regulatory agency has approved modafinil as an anti-obesity medication. The FDA-approved GLP-1 receptor agonists (semaglutide 2.4 mg as Wegovy, tirzepatide 2.5 to 15 mg as Zepbound) have strong Phase 3 trial data supporting weight reduction. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [20]. Modafinil has no comparable weight-loss efficacy data and no FDA obesity indication.

What Is the Difference Between Modafinil and Armodafinil, and Does It Affect Cigna Coverage?

Modafinil (Provigil) is a racemic mixture of R- and S-modafinil enantiomers. Armodafinil (Nuvigil) contains only the R-enantiomer and carries the same three FDA indications at lower mg doses (50 to 250 mg versus 100 to 400 mg for modafinil) [21]. Cigna treats them as separate agents with separate PA pathways, separate formulary tiers, and separate step-therapy requirements.

Generic armodafinil became available in 2016 after the Nuvigil patent expired, and it now occupies Tier 2 on most Cigna formularies just as generic modafinil does. If a member fails or is intolerant to generic modafinil, switching to generic armodafinil is a recognized clinical option and does not necessarily require a new full PA from scratch if the prescriber documents continuity of the same FDA-approved indication [22].

The pharmacokinetic difference matters clinically: armodafinil has a longer half-life (approximately 15 hours versus 12 to 13 hours for modafinil) and reaches peak plasma concentration later (2 to 4 hours post-dose versus 2 to 3 hours), which some patients report as smoother wakefulness throughout the day without a mid-afternoon dip [23]. Cigna's PA criteria for armodafinil mirror those for modafinil in terms of diagnosis codes and sleep study requirements.

What Should My Doctor Include in the Prior Authorization Letter?

A strong Cigna PA letter for Provigil runs two to three pages and contains seven specific elements that Cigna's pharmacy reviewers look for. Generic, boilerplate letters rarely succeed at the first submission.

The letter should open with the member's full name, date of birth, Cigna member ID, and the prescriber's NPI number. Then it should state the diagnosis with the ICD-10 code, summarize the objective sleep study findings with dates and numeric values (MSLT mean latency, AHI score, or actigraphy results), document the generic modafinil trial if applicable (dates, doses, and reason for switching), explain why brand Provigil is requested if brand is being requested, cite the relevant Cigna policy number, and close with the prescriber's board certification and contact information for peer-to-peer review.

The Centers for Medicare and Medicaid Services' 2023 prior authorization transparency rule requires that commercial insurers provide specific denial reasons, and Cigna complies by issuing an Explanation of Benefits (EOB) that cites the specific policy criterion not met [24]. Reading that criterion in the EOB and addressing it point-by-point in the appeal letter is more effective than re-submitting the same original documentation.